Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2000
05/11/2000CA2348446A1 Benzamide potassium channel inhibitors
05/11/2000CA2348392A1 Method for producing luteolin and luteolin derivatives
05/11/2000CA2348267A1 Novel inhibitors of impdh enzyme
05/11/2000CA2348234A1 Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
05/11/2000CA2348094A1 Method for improved imaging and photodynamic therapy
05/11/2000CA2347915A1 Enhanced radiation therapy
05/11/2000CA2347650A1 Transmembrane 4 proteins
05/11/2000CA2347188A1 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents
05/11/2000CA2347119A1 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
05/11/2000CA2347060A1 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
05/11/2000CA2346857A1 Implant with cavities containing therapeutic agents
05/11/2000CA2345697A1 Water-miscible pharmaceutical compositions of paclitaxel
05/11/2000CA2344972A1 Cancer immunotherapy and diagnosis using universal tumor associated antigens, including htert
05/11/2000CA2317113A1 Pharmaceutical composition having antitumor activity and process for the preparation thereof
05/11/2000CA2312430A1 N-oxides of heterocyclic compounds with tnf and pde-iv inhibiting activity
05/10/2000EP0998940A1 Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues
05/10/2000EP0998924A1 Antitumor agents
05/10/2000EP0998582A1 Methods for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells
05/10/2000EP0998573A2 Fusion proteins with an immunoglobulin hinge region linker
05/10/2000EP0998569A1 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
05/10/2000EP0998568A1 Mutant having uracil phosphoribosyl transferase activity
05/10/2000EP0998556A2 Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1)
05/10/2000EP0998473A1 Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
05/10/2000EP0998471A1 Substituted heterocyclic compounds, method for preparing and compositions containing same
05/10/2000EP0998455A1 Dihomo-seco-cholestanes with two unsaturated bones in the side chain
05/10/2000EP0998454A2 Metalloproteinase inhibitors
05/10/2000EP0998306A1 Liposomal compositions for the delivery of nucleic acid catalysts
05/10/2000EP0998305A2 Cytolysis of target cells by superantigen conjugates inducing t-cell activation
05/10/2000EP0998303A1 Biologically active materials
05/10/2000EP0998302A1 Methods of delaying development of hmfg-associated tumors using anti-idiotype antibody 11d10
05/10/2000EP0998299A1 ISOLATED PEPTIDES WHICH COMPLEX WITH HLA-Cw*16 MOLECULES, AND USES THEREOF
05/10/2000EP0998298A2 Method of an increasing the antigen presenting ability of monocytes
05/10/2000EP0998294A1 Ganglioside gm3 induced apoptosis of neural cells
05/10/2000EP0998293A1 Cytokine related treatments of disease
05/10/2000EP0998283A1 Calcilytic compounds
05/10/2000EP0998279A1 Pharmaceutical injection solution containing taxol
05/10/2000EP0998278A1 Hydroxy and ether-containing oxyalkylene esters and uses thereof
05/10/2000EP0998275A1 INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-kappaB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN
05/10/2000EP0800503B1 Novel trienoic retinoid compounds and methods
05/10/2000EP0762879B1 Stereochemical wortmannin derivatives
05/10/2000EP0743939B1 Aralkoxy and aralkylthio substituted azacyclic compounds as tachykinin antagonists
05/10/2000EP0736004B1 (2,4-disulfophenyl) n-tertiary butyl nitrone, its salts, and their use as pharmaceutical radical trapping agents
05/10/2000CN1252840A Adenovirus vector specific for cells expressing alpha fetoprotein and methods of use thereof
05/10/2000CN1252809A Modified TNF alpha molecules, DNA encoding such modified TNF alpha molecules and vaccines comprising such modified TNF alpha molecules and DNA
05/10/2000CN1252806A Dolastatin-15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
05/10/2000CN1252805A Compositions for treating or preventing prostatic cancer
05/10/2000CN1252800A Farnesyltransferase inhibiting quinazolinones
05/10/2000CN1252799A N-heterocyclic derivatives as NOS inhibitor
05/10/2000CN1252790A N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
05/10/2000CN1252788A Process for preparing pharmaceutical compounds
05/10/2000CN1252728A Dolastatin-15 derivatives in combination with taxanes
05/10/2000CN1252719A Pharmaceutical compositions for immunosuppression, anticancer and antiviral treatment
05/10/2000CN1252713A N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
05/10/2000CN1252689A Combined tumor suppressor gene therapy and chemotherapy in treatment of neoplasms
05/10/2000CN1252301A Cancer eliminating ointment compounding process
05/10/2000CN1252300A Compounding method of carcinomatosis resisting medicine
05/10/2000CN1252238A Stable powder tomato red agent preparation containing crystallinity large than 20% tomato red agent
05/10/2000CN1052233C Alkaloids from mappia foetida, the use and formulations containing them
05/10/2000CN1052231C 2-oxo-5-oxazolidone methyl compound their preparing method and medicinal composition containing them
05/10/2000CN1052229C 7-deoxy taxols and its medicinal composition
05/10/2000CN1052227C Oxazolidone used as adhesive receptor antagenists, its preparing method and medicinal composition containing them
05/09/2000US6060616 Antitumors agents; leukemia, ovarian carcinoma
05/09/2000US6060604 Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups
05/09/2000US6060588 Bap-1 proteins
05/09/2000US6060587 Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
05/09/2000US6060518 Polymer compositions for chemotherapy and methods of treatment using the same
05/09/2000US6060503 Antiestrogenic, anticarcinogenic stereospecific benzopyran derivative; breast cancer
05/09/2000US6060494 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
05/09/2000US6060475 Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof
05/09/2000US6060458 Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use
05/09/2000US6060449 Neovascularization inhibitor containing tissue factor pathway inhibitor
05/09/2000US6060303 Use in screening assays and as pharmaceuticals.
05/09/2000US6060275 Sprouty protein and coding sequence
05/09/2000US6060250 Human transferases
05/09/2000US6060239 Cellubrevin homologs
05/09/2000US6060066 First unit containing ricin toxoid vaccine and adjuvant and a second unit comprising a tumor-killing effective amount of ricin in sterile saline.
05/09/2000US6060037 Conjugated compounds which comprise an st receptor binding moiety and a radiostable active moiety
05/09/2000US6060036 Radioactive seed implants
05/09/2000CA2112239C Enantiomeric hydroxylated xanthine compounds
05/09/2000CA2058940C Targeted liposomes and methods for liposome-protein coupling
05/04/2000WO2000024922A1 Method for producing in vivo proteins chemically diversified by incorporating non-standard amino acids
05/04/2000WO2000024913A2 Mn gene and protein
05/04/2000WO2000024911A2 Human phospholipases
05/04/2000WO2000024897A1 Cell surface molecule-induced macrophage activation
05/04/2000WO2000024896A2 Biological material for preparing pharmaceutical compositions for treating mammals
05/04/2000WO2000024890A1 Novel g protein-coupled receptor proteins, dnas thereof and ligands to the same
05/04/2000WO2000024886A1 Prv-1 gene and the use thereof
05/04/2000WO2000024885A2 p53 MORPHOLINO-BASED ANTISENSE
05/04/2000WO2000024782A2 Modified peptides, comprising an fc domain, as therapeutic agents
05/04/2000WO2000024779A1 Lysine-rich statherin protein
05/04/2000WO2000024778A1 Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
05/04/2000WO2000024755A1 Ovary-specific genes and proteins
05/04/2000WO2000024751A1 Chelating agents for radioimmunotherapy
05/04/2000WO2000024745A1 PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
05/04/2000WO2000024744A1 Bicyclic nitrogen heterocycles
05/04/2000WO2000024734A1 Lipoic acid derivatives and their use in treatment of disease
05/04/2000WO2000024724A1 Thiazole-derivatives
05/04/2000WO2000024719A1 Prostaglandin endoperoxide h synthase biosynthesis inhibitors
05/04/2000WO2000024718A1 Serine protease inhibitor
05/04/2000WO2000024710A1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
1 ... 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 ... 2211